Navigation Links
Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases

timately causing inflammation. Chronic inflammatory diseases afflict millions of people worldwide and are a physical, social and economic burden to patients and their families. Despite the burden and prevalence of inflammatory diseases, there have been relatively few innovative breakthroughs in identifying their cause, treatment or cure.

About CC-10004

CC-10004 is a member of a proprietary pipeline of novel small molecules with anti-inflammatory activities that inhibit the production of multiple proinflammatory mediators including, PDE-4, TNF-alpha, interleukin-2 (IL-2), interferon-gamma, leukotrienes, and nitric oxide synthase. CC-10004 is our lead investigational drug in this class of anti-inflammatory compounds. Based on promising results from proof-of-mechanism studies, Celgene is accelerating the evaluation of clinical and regulatory strategies around the development of CC-10004 and other anti-inflammatory agents into clinical trials designed to determine their potential across a broad range of debilitating inflammatory diseases.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:5/28/2015)... Texas , May 28, 2015 ... segments the concerned market with analysis and forecast of ... 2014 and is estimated to reach $1,177.8 million by ... 2019. Browse through the TOC of Mannequin-Based ... trends and segments, with help of various tables and ...
(Date:5/28/2015)... May 28, 2015  Pharmaceutic Labs announces its ... section 503B of the FDA,s Drug Quality and ... company is subject to Current Good Manufacturing Practice ... according to the highest standards of CGMP 21 ... To continuously comply with FDA regulations and ensure ...
(Date:5/28/2015)... N.J. , May 28, 2015  Janssen Pharmaceuticals, ... announced the initiation of CALLISTO, a new comprehensive clinical ... patients with active cancer. The studies are evaluating the ... clots in patients with a wide range of cancer ... risk of venous thromboembolism (VTE), which is a blood ...
Breaking Medicine Technology:Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 2Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 3New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 2New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 3New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 4New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 5New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 6New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 7New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 8New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 9New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 10New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 11New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer 12
... 2011 Due to significant recent growth in its x-ray ... has announced several changes to its sales and marketing operations. ... distributor and supplier in the newly created position as ... News headquarters. Porter has had experience as a division sales ...
... Vycor Medical, Inc. announces that  Alvaro Pascual-Leone, MD, PhD ... Strategic Advisory Board of its NovaVision, Inc. subsidiary. ... at Harvard Medical School; Director of the Berenson-Allen Center ... Clinical Research Unit; and an Attending Neurologist at Beth ...
Cached Medicine Technology:Burlington Medical Supplies Reorganizes Sales and Marketing Operations 2Vycor Medical, Inc. Announces Alvaro Pascual-Leone, MD, PhD as Head of the Strategic Advisory Board of its NovaVision, Inc. Subsidiary 2Vycor Medical, Inc. Announces Alvaro Pascual-Leone, MD, PhD as Head of the Strategic Advisory Board of its NovaVision, Inc. Subsidiary 3Vycor Medical, Inc. Announces Alvaro Pascual-Leone, MD, PhD as Head of the Strategic Advisory Board of its NovaVision, Inc. Subsidiary 4
(Date:5/28/2015)... May 28, 2015 ISMETT , a ... Italy, boosted the Sicilian economy by €132.5 million in expenditure ... benefit of more than €73 million by retaining patients who ... to a new study by the Battelle Memorial Institute. At ... research, training and advanced health care management that is transforming ...
(Date:5/28/2015)... May 28, 2015 Workers’ compensation costs per ... state, a recent study by the Workers Compensation Research ... a three-year period. , The WCRI study, CompScope™ Benchmarks ... workers missed seven days or more of work with those ... average 2011 Michigan claim was 4 percent lower than similar ...
(Date:5/28/2015)... Baptist Medical Center Jacksonville has added ... acute stroke or other neurological conditions. , The new ... few in the country and the first in Florida ... as brain aneurysms. , “Baptist Health is committed ... who are impacted by stroke,” said Nicole Thomas, Baptist ...
(Date:5/28/2015)... 2015 Dr. Paul Vitenas, one of ... announced that the new Houston Surgery Center he recently ... Accreditation of Ambulatory Surgery Facilities awarded this accreditation to ... , According to Dr. Vitenas, the certificate was given ... a Class C ambulatory surgery facility. This certification means ...
(Date:5/28/2015)... Francisco,CA (PRWEB) May 28, 2015 ... creating technology that advances sexual health and wellbeing ... the University of San Francisco (USF) will be ... college sexual assault recording and reporting system. ... empowering, transparent, and confidential reporting experience for college ...
Breaking Medicine News(10 mins):Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 3Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3
... of the most effective weapons to stop the spread of ... Haiti since the devastating earthquake last year. A technique ... workers to test water sources that could be contaminated with ... coated onto iron oxide nanoparticles and then added to a ...
... say their efforts in the laboratory may lead to ... but chemistry students in the School of Science ... the science of chemistry they are actually synthesizing molecules ... as potential drug treatments or cures for such devastating ...
... we advise about alcohol consumption?" was recently published by Maurizio ... Leon argues that the message of health benefits of moderate ... in the general population." His reasons included (1) many ... consumption of wine, beer or spirits, and alcohol metabolism may ...
... Blondie singer Debbie Harry and The Verve,s Richard Ashcroft. They ... raise funds for PDT. The work carried out by ... School and Royal Cornwall Hospital in Truro, UK, was ... 30,000, which came from the proceeds of the concert. ...
... at a busy intersection flashes the WALK sign, people with ... it across the street in time. New Northwestern Medicine research ... walk fast enough if they lead physically active lives. ... they can walk," said Dorothy Dunlop, associate professor of medicine ...
... , TUESDAY, Jan. 18 (HealthDay News) -- Stringent mental health ... and behavioral problems among U.S. Army soldiers in Iraq by ... other things, suicidal thoughts and actions fell by half, according ... Tuesday in advance of publication in an upcoming print issue ...
Cached Medicine News:Health News:Special sugar, nanoparticles combine to detect cholera toxin 2Health News:Special sugar, nanoparticles combine to detect cholera toxin 3Health News:Molecules made by IUPUI students may have potential to cure diseases 2Health News:Molecules made by IUPUI students may have potential to cure diseases 3Health News:Critique 029: What should we advise about alcohol consumption? A debate amongst scientists 2Health News:When you can't walk fast enough to cross busy streets 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: